Why Children

According to many studies, children are the ideal population to study novel therapeutic strategies for HIV remission, because:

Children and adolescents living with HIV have to remain in therapy for their whole life. 

This increases their risk of experiencing drug toxicity, poor adherence to treatment and viral resistance. 

The unique features of early-treated children as a model. The panel summarises the main differences among early-treated children and other model populations. Infants with HIV treated within 2–3 months of life rarely exhibit HIV-specific immunity, have a more limited viral reservoir and viral diversity, greater thymic output, lower numbers of central memory T cells and greater ability to develop and maintain protective responses to vaccination, compared with other population models.
From Palma P. et al.  J Virus Erad 2015

A life changer is needed. 

By setting up the EPIICAL Consortium, Penta has gathered a multidisciplinary group of researchers from across the world for a common purpose. Their continued commitment is central to further HIV research and finding a cure. 

Reasons for the urgent need for new therapeutic strategies for children with perinatally acquired HIV.
From Palma P. et al.  J Virus Erad 2015
Stay in the loop

Sign up with your email address to receive news and updates.